Hims & Hers Health (NYSE:HIMS) Given New $31.00 Price Target at Needham & Company LLC

Hims & Hers Health (NYSE:HIMS - Free Report) had its target price upped by Needham & Company LLC from $28.00 to $31.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also issued reports on HIMS. Piper Sandler restated a "neutral" rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Bank of America cut Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Canaccord Genuity Group increased their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a "buy" rating in a research report on Monday, December 2nd. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research note on Wednesday, November 6th. Finally, TD Cowen reaffirmed a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $24.07.

Hims & Hers Health Price Performance

Hims & Hers Health stock traded up $0.19 during mid-day trading on Monday, hitting $26.82. 9,029,169 shares of the company were exchanged, compared to its average volume of 8,615,215. Hims & Hers Health has a 12-month low of $8.14 and a 12-month high of $35.02. The business's 50 day simple moving average is $26.73 and its two-hundred day simple moving average is $21.53. The company has a market capitalization of $5.86 billion, a P/E ratio of 60.96 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm's quarterly revenue was up 77.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) EPS. Equities research analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction on Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the sale, the chief financial officer now owns 145,763 shares of the company's stock, valued at $2,960,446.53. The trade was a 64.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 188,888 shares of the company's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the transaction, the chief executive officer now directly owns 67,015 shares of the company's stock, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,064,514 shares of company stock worth $26,712,334. Corporate insiders own 17.71% of the company's stock.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of HIMS. Principal Financial Group Inc. grew its position in shares of Hims & Hers Health by 763.4% during the second quarter. Principal Financial Group Inc. now owns 143,793 shares of the company's stock worth $2,903,000 after buying an additional 127,138 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in Hims & Hers Health during the 2nd quarter worth $479,000. Van ECK Associates Corp bought a new stake in shares of Hims & Hers Health in the 2nd quarter worth about $111,000. Rhumbline Advisers raised its stake in shares of Hims & Hers Health by 50.1% in the 2nd quarter. Rhumbline Advisers now owns 268,420 shares of the company's stock valued at $5,419,000 after purchasing an additional 89,535 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company's stock worth $393,000 after purchasing an additional 1,212 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.